[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pain-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pain-cancer":153},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,76,101,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100528404","upfront-eus-cgncpn-vs-conventional-step-up-approach-for-inoperable-painful-pancreatic-cancer-100528404",false,"NCT06160323","Upfront EUS CGN\u002FCPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer","Upfront Endoscopic Ultrasound-guided Celiac Ganglion Neurolysis Versus Conventional Step-up Approach for Patients With Painful, Inoperable Pancreatic Cancer","Inclusion Criteria:\n\n1. Age \\>= 18 years old\n2. Diagnosed to have inoperable pancreatic cancer\n3. Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS \\>= 3\n4. Karnofsky performance status \\>= 60\n5. Planned for EUS examination and\u002For biopsy of the pancreatic tumor\n\nExclusion Criteria:\n\n1. Allergy to bupivacaine, or alcohol\n2. Potentially operable after neoadjuvant therapy\n3. Expected survival of less than 3 months\n4. Patient who is already on opioids for pain control\n5. Previous percutaneous or EUS-guided CGN\u002F CPN\n6. Recurrent pancreatic tumors after operation\n7. Uncorrectable coagulopathy\n8. Inability or unwillingness to provide informed consent","ALL","18 Years",{"count":19,"type":20},94,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainstay of treatment. However, patients develop opioid-related adverse effects. EUS-guided celiac plexus neurolysis (CPN) and celiac ganglion neurolysis (CGN) has been shown to provide high efficacy for pain control. The optimal timing, however, is in debate.",[26,27,28],"Pancreatic Cancer Non-resectable","Tumor Pancreas","Pain Cancer",[26,30,31],"tumor pain","endoscopic ultrasound-guided celiac ganglion neurolysis","RECRUITING","2026-05-04",{"date":35,"type":36},"2026-05-06","ACTUAL",{"date":38,"type":36},"2023-11-10",{"date":40,"type":20},"2028-07-31",{"name":42,"class":43},"Chinese University of Hong Kong","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100618877","ultrasound-guided-external-oblique-intercostal-plane-block-versus-erector-spinae-block-for-post-hepatectomy-pain-100618877","NCT07337330","Ultrasound Guided External Oblique Intercostal Plane Block Versus Erector Spinae Block for Post Hepatectomy Pain","Comparative Study Between Ultrasound Guided External Oblique Intercostal Plane Block and Erector Spinae Block for Postoperative Analgesia in Hepatectomy Incision in Cancer Patients","Inclusion Criteria:\n\n* Cancer patients undergoing hepatectomy under general anaesthesia\n* Aged 18 years or older\n* ASA II \\& III\n* BMI \\>20kg\u002Fm2 and \\\u003C35kg\u002Fm2\n\nExclusion Criteria:\n\n* History of psychiatric disorders or history of major depression.\n* Major medical conditions (heart failure , chronic kidney disease ,patient on dialysis)",{"count":53,"type":20},52,[23],"Management of acute post-operative pain has received keen attention in recent years with considerable concurrent advancement in the field.\n\nThe importance of effective pain relief has long been realised, and acute pain services (APS) are operational in majority of the hospitals in the developed world for decades.\n\nPostoperative pain following abdominal surgery if severe enough may cause several side effects as \"splinting, hypoventilation, atelectasis, immobility, hypercoagulability, thromboembolic events, vasoconstriction, tachycardia, increased systemic vascular resistance, dysrhythmias and cardiac ischemia in susceptible patients, insomnia, anxiety, feeling of helplessness\".\n\nUltrasound-guided fascial plane blocks have been rapidly incorporated into regional anaesthesia practice in recent years as an alternative to neuraxial techniques and involve injection into a tissue plane to provide analgesia in various anatomic areas.\n\nExternal oblique intercostal plane block (EOIPB) is a novel block, which has been described as an important modification of the fascial plane blocks that can consistently involve the upper lateral abdominal walls.\n\nThe erector spinae plane (ESP) block is a new regional aesthetic technique that can be used to provide analgesia for a variety of surgical procedures or to manage acute or chronic pain. The technique is relatively easy to perform on patients.\n\nThe ESPB involves injection of local anaesthetic in the erector spinae fascial plane, superficial to the tip of the transverse process of the vertebra and deep to the erector spinae muscle.",[57,58,59],"Pain; Cancer","Hepatectomy","Nerve Block",[61,62,63,64,65],"hepatectomy","erector spinae block","external oblique intercostal plane block","liver cancer","ultrasound guided","NOT_YET_RECRUITING","2026-01-29",{"date":69,"type":36},"2026-02-02",{"date":71,"type":20},"2026-01-15",{"date":73,"type":20},"2026-09-15",{"name":75,"class":43},"National Cancer Institute, Egypt",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100593074","phase-4-determining-the-effect-of-abiraterone-on-the-metabolism-of-oxycodone-in-men-with-prostate-cancer-the-enable-study-100593074","NCT07001709","Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)","The Effect of Abiraterone on the Metabolism of Oxycodone","ENABLE","Inclusion Criteria:\n\n* Diagnosed prostate cancer;\n* Males aged 18 years or older;\n* Treated with abiraterone 1000 mg once daily for at least 10 days (abiraterone arm).\n* Not treated with abiraterone 1000 mg once daily for at least 10 days (control arm).\n\nExclusion Criteria:\n\n* Use of oxycodone short acting \\\u003C48 hours, or long acting \\\u003C96 hours prior to the study day;\n* Use of other opioids in the 14 days prior to the study day (see also appendix A);\n* Use of other medication that has pharmacokinetic or pharmacodynamics interactions with oxycodone (see also appendix A);\n* Arm 1: dose reduction or successive days of treatment interruption within 10 days prior to the study day (arm 1);\n* Arm 2: treatment with abiraterone within 10 days prior to the study day;\n* A body mass index (BMI) outside the range of 18 - 30 kg\u002Fm2;\n* If hypersensitive to oxycodone;\n* patients suffering from diarrhea\n* If any type of abnormality; active or symptomatic viral hepatitis or chronic liver disease (e.g. classification with Child-Pugh B, Child-Pugh C);\n* Known metastases in the liver that would affect drug metabolism;\n* Patients with a CYP3A4 or CYP2D6 polymorphism;\n* Moderate-severe renal dysfunction (GFR \\\u003C60 ml\u002Fmin\u002F1.73m2) that affects drug metabolism ;\n* Subjects with significant respiratory depression resulting in the need of oxygen therapy or objective hypoventilation (respiratory rate \\\u003C12\u002Fmin);\n* Hypercapnia (venous pCO2 outside the range of 5.5 - 6.7; pH outside the range 7.30 - 7.40);\n* Subjects with, a history of bronchial asthma, chronic obstructive pulmonary disease or pulmonary heart disease;\n* Subjects who started their first cycle of chemotherapy during the 2 weeks before the study day;\n* Major surgery within 1 month prior to screening or planned surgery;\n* A history of drug abuse\n* Patients receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine) and\u002For suffering from opioid withdrawal\n* Patients with evidence of clinically significant gastrointestinal disease;\n* Patients who are contraindicated for blood sampling;\n* Unable to swallow solid, oral dosage forms whole with water;\n* Participation in a clinical trial study at the time of enrolment or within 30 days or 5 half-lives of enrolment, whichever is longer;\n* Previous gastric bypass or gastric band surgery.","MALE",{"count":86,"type":20},29,[88],"PHASE4","Prostate cancer often leads to bone metastases, which require adequate pain management with opioids such as oxycodone. This study investigates whether abiraterone - a drug used in the treatment of prostate cancer - affects the pharmacokinetics of oxycodone in order to improve pain management.",[91,28],"Prostate Cancer","2025-05-23",{"date":94,"type":36},"2025-06-03",{"date":96,"type":36},"2024-04-12",{"date":98,"type":20},"2026-01-30",{"name":100,"class":43},"Deventer Ziekenhuis",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":44},"100585096","phase-4-real-world-study-of-oxycodonenaloxone-sustained-release-tablets-mimeixin-for-patients-with-severe-cancer-pain-100585096","NCT06897917","Real World Study of Oxycodone\u002FNaloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain","Inclusion Criteria:\n\n* Age ≥ 18 years old, with a histological or pathological diagnosis of advanced cancer.\n* Be diagnosed with severe (NRS ≥ 7 points) cancer pain, requiring regular opioid therapy.\n* Diagnosed with OIC according to the Rome IV diagnostic criteria for OIC, with a BFI score ≥ 30.\n* Determined by the investigator to be eligible for treatment with oxycodone\u002Fnaloxone sustained-release tablets.\n* Estimated survival period of more than 3 months.\n* Voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with contraindications to oxycodone\u002Fnaloxone sustained-release tablets (including allergy to the active ingredients or any excipients of this product; severe respiratory depression accompanied by hypoxemia and\u002For hypercapnia; severe chronic obstructive pulmonary disease; pulmonary heart disease; severe bronchial asthma; paralytic ileus caused by non-opioid drugs; moderate to severe liver function impairment).\n* Patients with structural malformations of the gastrointestinal tract (such as intestinal obstruction, stenosis), other known gastrointestinal diseases\u002Fsymptoms (including cancer metastasis to the digestive tract), or gastrointestinal digestion and absorption disorders.\n* Patients with language communication barriers, cognitive impairments or mental illnesses, intracranial metastasis of tumors with consciousness disorders, or consciousness disorders caused by other reasons.\n* Other situations that the investigator judges as unsuitable for inclusion in the study.",{"count":108,"type":20},203,[88],"This study is a prospective, single-arm, multicenter, real-world study to evaluate effect of bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain.",[112,28],"Opioid-Induced Constipation",[114,115,116],"opioid-induced constipation","severe cancer pain","Oxycodone\u002Fnaloxone sustained-release tablets","2025-03-26",{"date":119,"type":36},"2025-03-27",{"date":121,"type":20},"2025-04",{"date":123,"type":20},"2025-12",{"name":125,"class":126},"Henan Cancer Hospital","OTHER_GOV",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":149,"leadSponsor":151,"locationsCount":44},"100574192","evaluate-the-efficacy-of-radiofrequency-ablationvertebroplasty-with-or-without-sbrt-for-treating-painful-spinal-vertebral-metastases-100574192","NCT06756087","Evaluate the Efficacy of Radiofrequency Ablation\u002FVertebroplasty with or Without SBRT for Treating Painful Spinal Vertebral Metastases","Radiofrequency Ablation\u002FVertebroplasty Versus Radiofrequency Ablation\u002FVertebroplasty Combined with SBRT for Painful Spinal Vertebral Metastases: a Multicenter, Practical, Randomized, Controlled, Non-Inferiority Clinical Study","Inclusion Criteria:\n\n1. The subject voluntarily participates in this study, and both the patient and their family sign an informed consent form. The subject demonstrates good compliance and cooperates with follow-up.\n2. Age 18 or older, no gender restrictions.\n3. The target population for this trial consists of patients with bone metastases from malignant tumors confirmed by pathology or imaging, with lesions located between T5 and L5. The number of affected vertebral sites is fewer than three, and the lesions are mainly osteolytic, affecting primarily the vertebral bodies.\n4. Expected survival is greater than three months.\n5. Initial diagnosis with an NPRS pain score \\> 3.\n6. ECOG performance status score of 0-2.\n7. The function of vital organs meets the following requirements: a) Adequate bone marrow function: WBC ≥ 3.0×10\\^9\u002FL; absolute neutrophil count (ANC) ≥ 1.5 ×10\\^9\u002FL; lymphocyte count ≥ 6.0×10\\^8\u002FL; platelet count ≥ 50×10\\^9\u002FL, with no blood transfusion within 14 days prior to the first cellular therapy; hemoglobin ≥ 10.0 g\u002FdL. b) Adequate liver and kidney function: total bilirubin ≤ 2.0×ULN, AST and ALT \\\u003C 2.5×ULN; serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 50 ml\u002Fmin (calculated using the Cockcroft-Gault formula). c) Coagulation function: INR ≤ 1.5×ULN, APTT ≤ 1.5×ULN. d) Adequate cardiovascular function: left ventricular ejection fraction (EF) ≥ 50%, QTcF interval ≤ 450 ms for males and ≤ 470 ms for females.\n8. Use of at least one medically approved contraceptive method (e.g., surgical sterilization, oral contraceptives, intrauterine device, abstinence, or barrier methods with spermicide) for at least six months.\n\nExclusion Criteria:\n\n1. Subjects with no measurable lesions;\n2. Known brain metastasis and\u002For clinically suspected brain metastasis (subjects with asymptomatic brain metastasis or clinically stable brain metastasis for more than three months after local treatment can be included);\n3. Subjects whose target lesions received radiotherapy within the past two years;\n4. Tumor types sensitive to radiotherapy, including malignant lymphoma, testicular seminoma, Wilms tumor, neuroblastoma, medulloblastoma, Ewing sarcoma, and small cell tumors.\n5. Spinal metastases involving spinal appendages, destruction of the posterior wall of the vertebral canal, or compression of the spinal dura mater;\n6. Subjects preparing for or who have previously undergone tissue\u002Forgan transplantation;\n7. Subjects with active infections or unexplained fever \\>38.5℃ during screening or before treatment;\n8. Patients with active pulmonary tuberculosis (TB), currently receiving anti-TB treatment or treated for TB within the past year before screening;\n9. Positive syphilis serology test;\n10. Known history of HIV-positive test or known acquired immunodeficiency syndrome (AIDS);\n11. Active hepatitis B: hepatitis B surface antigen (HBsAg) positive with HBV DNA levels exceeding 10,000 IU\u002Fml; hepatitis C: hepatitis C antibody (HCV Ab) positive with HCV RNA levels exceeding 1,000 IU\u002Fml; co-infection with hepatitis B and hepatitis C;\n12. Cardiovascular disease meeting any of the following: a. Congestive heart failure with NYHA classification ≥ III; b. Severe arrhythmia requiring medication; c. Acute myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, or stenting within six months before initial dosing; d. Left ventricular ejection fraction (LVEF) \\\u003C 50%; e. QTcF interval \\> 450 ms for males and \\> 470 ms for females, or risk factors for torsades de pointes, such as clinically significant hypokalemia, family history of long QT syndrome, or familial arrhythmias (e.g., Wolff-Parkinson-White syndrome) as determined by the investigator;\n13. Uncontrolled hypertension (defined as systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg despite standardized antihypertensive treatment);\n14. Subjects deemed by the investigator to have serious uncontrolled diseases or other conditions that may affect participation in the study or render them unsuitable for study treatment.",{"count":135,"type":20},120,[23],"This study is a prospective, multicenter, open, practical, randomized controlled, non inferiority effect clinical study initiated by researchers, which aims to evaluate the clinical efficacy and safety of radiofrequency ablation\u002Fvertebroplasty and radiofrequency ablation\u002Fvertebroplasty combined with SBRT in the treatment of painful spinal metastases. This study plans to include about 120 cases in about 3 research centers nationwide, including the Department of bone oncology of Shanghai First People's Hospital (main center, 60 cases), the Department of bone oncology of the Third Affiliated Hospital of Southern Medical University (sub center 1, 30 cases), and the Department of bone oncology of Peking University People's Hospital (sub center 2, 30 cases). The patient was diagnosed with spinal metastasis of malignant tumor and had pain of more than 3 points. The subjects with spinal metastasis located at t5-l5 were selected for clinical research. All patients were treated with RFA\u002FPVA minimally invasive surgery. In principle, no more than 2 vertebral bodies were treated. All patients will receive MRI\u002FCT examination of the affected spine within 6 weeks before enrollment to determine the degree of spinal involvement. All patients were randomly divided into experimental group and control group after minimally invasive surgery, the ratio was 1:1. The patients in the experimental group recovered to the original system treatment about two weeks after minimally invasive surgery; The control group began to receive SBRT radiotherapy of the surgical vertebral body in about two weeks, and the radiotherapy time was two weeks. According to the recommendations of the Department of radiotherapy, SBRT radiotherapy should use any of the following dose and grading scheme: 4 times 24gy, 5 times 30Gy, 6 times 36Gy, 7 times 42GY. The patients in the two groups were followed up after treatment, and evaluated at 1, 2 and 4 weeks and 3, 6 and 12 months after treatment. The NRPS pain degree and pafi pain function comprehensive score were evaluated, and the local lesions were evaluated at 1, 3, 6 and 12 months after operation. To evaluate the local control of spinal metastases, pain improvement and quality of life changes of the two treatment strategies.",[139,140,28],"Spinal Metastases","Local Control",[142,143,144],"spinal metastases","Radiofrequency Ablation","Stereotactic radiotherapy","2024-12-24",{"date":147,"type":36},"2025-01-01",{"date":147,"type":20},{"date":150,"type":20},"2026-12-31",{"name":152,"class":43},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","Pain, Cancer"]